Targeted prodrug design to optimize drug delivery
- 1 March 2000
- journal article
- review article
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (1) , 48-58
- https://doi.org/10.1208/ps020106
Abstract
Classical prodrug design often represents a nonspecific chemical approach to mask undesirable drug properties such as limited bioavailability, lack of site specificity, and chemical instability. On...Keywords
This publication has 75 references indexed in Scilit:
- Direct Evidence for Peptide Transporter (PepT1)-Mediated Uptake of a Nonpeptide Prodrug, ValacyclovirBiochemical and Biophysical Research Communications, 1998
- Valacyclovir: A Substrate for the Intestinal and Renal Peptide Transporters PEPT1 and PEPT2Biochemical and Biophysical Research Communications, 1998
- Peptide transportersCurrent Opinion in Nephrology and Hypertension, 1996
- Molecular cloning and tissue distribution of rat peptide transporter PEPT2Biochimica et Biophysica Acta (BBA) - Biomembranes, 1996
- Prodrugs in cancer chemotherapyThe International Journal of Cell Cloning, 1995
- Thymidine kinase-mediated killing of rat brain tumorsJournal of Neurosurgery, 1993
- ProdrugsDrugs, 1985
- Peptide transport in rabbit kidney. Studies with l-carnosineBiochimica et Biophysica Acta (BBA) - Biomembranes, 1982
- Pro-drugs: An Overview and DefinitionPublished by American Chemical Society (ACS) ,1975
- Rationale for Design of Biologically Reversible Drug Derivatives: ProdrugsJournal of Pharmaceutical Sciences, 1975